Market Snapshot

BSE Sensex: 74563.92 -1.93%
BSE 500: 33516.43 -2.29%
BSE 200: 10577.12 -2.22%
BSE 100: 24324.92 -2.15%
BSE BANKEX: 60462.88 -2.44%
BSE IT: 28151.52 -1.73%
Nifty 50: 23151.1 -2.06%
Nifty 500: 21391.2 -2.31%
Nifty 200: 13018.25 -2.25%
Nifty 100: 23849.25 -2.16%
Nifty Midcap 100: 54761.1 -2.65%
Nifty Small 100: 15895.25 -2.51%
Nifty IT: 29071.25 -1.72%
Nifty PSU Bank: 8516.55 -3.72%

News:

GE Power India CFO Aashish Gha...
Meta Infotech secures renewal ...
Prostarm Info bags Rs 7-cr sol...
3i Infotech bags cloud service...
Dilip Buildcon bags Rs 160-cr ...

Astrazeneca Pharma India Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

13 Mar 2026 | 03:59 PM

8,389.85

-209.00 (-2.43%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

9.52%

Return (1Y)

Beaten BSE Healthcare by 0.64%
More Volatile

1.96%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.08%
Not so consistent

5/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

10,653

6,502

News & Announcements

Astrazeneca Pharma India appoints Director - Legal
4 days ago

Astrazeneca Pharma India appoints Director - Legal

11 - Mar - 2026 12:00 | 4 days ago

The board of Astrazeneca Pharma India has appointed Sandhya Tejaswini Amanna as Director - Legal, with effect from 18 March 2026.
Powered by Capital Market - Live News
Astrazeneca Pharma India standalone net profit rises 5.64% in the December 2025 quarter
31 days ago

Astrazeneca Pharma India standalone net profit rises 5.64% in the December 2025 quarter

12 - Feb - 2026 12:00 | 31 days ago

Net profit of Astrazeneca Pharma India rose 5.64% to Rs 32.59 crore in the quarter ended December 2025 as against Rs 30.85 crore during the previous quarter ended December 2024. Sales rose 38.90% to Rs 611.57 crore in the quarter ended December 2025 as against Rs 440.29 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 611.57 440.29 39

OPM % 7.33 17.49 -

PBDT 48.90 84.64 -42

PBT 45.06 75.57 -40

NP 32.59 30.85 6

Powered by Capital Market - Live News
Astrazeneca Pharma India schedules board meeting
43 days ago

Astrazeneca Pharma India schedules board meeting

31 - Jan - 2026 12:00 | 43 days ago

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 11 February 2026.
Powered by Capital Market - Live News
AstraZeneca Pharma gets CDSCO nod for import and sale of Datverzo in India
87 days ago

AstraZeneca Pharma gets CDSCO nod for import and sale of Datverzo in India

18 - Dec - 2025 12:00 | 87 days ago

This authorization from the Central Drugs Standard Control Organization (CDSCO) marks the introduction of this treatment as a new drug in the Indian market.
This approval allows Datverzo to be used for treating adult patients with specific types of advanced, hormone-receptor-positive and HER2-negative breast cancer.
The treatment is intended for those who have already undergone endocrine-based therapy and chemotherapy for disease that is either metastatic or cannot be surgically removed.
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for the specified indication, subject to the receipt of related statutory approvals, if any.
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.
The company?s standalone net profit shed 2.88% to Rs 54.22 crore in Q2 FY26 as against Rs 55.83 crore posted in Q1 FY26. Revenue from operations rose 6.22% QoQ to Rs 559.09 crore in the quarter ended 30 September 2025. On a year on year (YoY) basis, the company?s net profit surged 41.08% while revenue from operations increased 37.03% in Q2 FY26.
The scrip shed 0.36% to currently trade at Rs 8993 on the BSE.

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

MF shareholding in Astrazeneca Pharma India Ltd has increased by 8.73% since past 3 Months
FII shareholding in Astrazeneca Pharma India Ltd has decreased by -7.51% since past 1 Year
MF shareholding in Astrazeneca Pharma India Ltd has increased by 7.69% since past 1 Year
Astrazeneca Pharma India Ltd has the 2nd highest P/Bratio according to FY202503 data among stocks in Pharmaceuticals Sector

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	611.57	440.29	39
OPM %	7.33	17.49	-
PBDT	48.90	84.64	-42
PBT	45.06	75.57	-40
NP	32.59	30.85	6

General Notifications

My Notifications

Research Notifications

Astrazeneca Pharma India Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

8,389.85 -209.00 (-2.43%)

News & Announcements

Price vs Volume

Stock Trivia

Astrazeneca Pharma India Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

8,389.85

-209.00 (-2.43%)